Aptahem Past Earnings Performance
Past criteria checks 0/6
Aptahem has been growing earnings at an average annual rate of 11.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 71.8% per year.
Key information
11.7%
Earnings growth rate
46.5%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 71.8% |
| Return on equity | -18.2% |
| Net Margin | -439.0% |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Aptahem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3 | -11 | 13 | 0 |
| 31 Dec 23 | 3 | -11 | 13 | 0 |
| 30 Sep 23 | 3 | -10 | 13 | 0 |
| 30 Jun 23 | 3 | -10 | 13 | 0 |
| 31 Mar 23 | 3 | -9 | 13 | 0 |
| 31 Dec 22 | 3 | -9 | 13 | 0 |
| 30 Sep 22 | 2 | -12 | 15 | 0 |
| 30 Jun 22 | 1 | -15 | 17 | 0 |
| 31 Mar 22 | 1 | -18 | 19 | 0 |
| 31 Dec 21 | 0 | -28 | 28 | 0 |
| 30 Sep 21 | 0 | -35 | 35 | 0 |
| 30 Jun 21 | 0 | -34 | 34 | 0 |
| 31 Mar 21 | 0 | -33 | 33 | 0 |
| 31 Dec 20 | 0 | -24 | 24 | 0 |
| 30 Sep 20 | 0 | -15 | 14 | 0 |
| 30 Jun 20 | 0 | -16 | 16 | 0 |
| 31 Mar 20 | 0 | -17 | 17 | 0 |
| 31 Dec 19 | 0 | -17 | 17 | 0 |
| 30 Sep 19 | 0 | -18 | 1 | 0 |
| 30 Jun 19 | 0 | -16 | -1 | 0 |
| 31 Mar 19 | 0 | -21 | 4 | 0 |
| 31 Dec 18 | 0 | -21 | 4 | 0 |
| 30 Sep 18 | 0 | -19 | 12 | 0 |
| 30 Jun 18 | 0 | -17 | 10 | 0 |
| 31 Mar 18 | 0 | -11 | 4 | 0 |
| 31 Dec 17 | 0 | -10 | 3 | 0 |
| 30 Sep 17 | 0 | -10 | 4 | 0 |
| 30 Jun 17 | 0 | -10 | 4 | 0 |
| 31 Mar 17 | 0 | -10 | 4 | 0 |
| 31 Dec 16 | 0 | -10 | 4 | 0 |
| 30 Sep 16 | 0 | -10 | 7 | 0 |
| 30 Jun 16 | 0 | -8 | 6 | 0 |
| 31 Mar 16 | 0 | -6 | 3 | 0 |
| 31 Dec 15 | 0 | -6 | 3 | 0 |
Quality Earnings: APTA is currently unprofitable.
Growing Profit Margin: APTA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APTA is unprofitable, but has reduced losses over the past 5 years at a rate of 11.7% per year.
Accelerating Growth: Unable to compare APTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.8%).
Return on Equity
High ROE: APTA has a negative Return on Equity (-18.22%), as it is currently unprofitable.